Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma
Abroad (travel likely)RecruitingPHASE4
Conditions
Vaccine · Streptococcus Pneumoniae · Lymphoma, Non-Hodgkin
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Chu Angers, Angers, France
Contact: Study coordinator (Jérôme PAILLASSA, Dr)CHU Bordeaux, Bordeaux, France
CHU Limoges, Limoges, France
Contact: Study coordinator (Arnaud JACCARD, Pr)Chu Nantes, Nantes, France
Ch Perigueux, Périgueux, France
Contact: Study coordinator (Claire CALMETTES, Dr)CHU Poitiers, Poitiers, France
Contact: Study coordinator (Cécile GRUCHET, Dr)CHU Tours, Tours, France
Contact: Study coordinator (Antoine MACHET, Dr)